A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

Launched by NOVO NORDISK A/S · Jan 13, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new medication called CagriSema to see how effectively it helps people with obesity lose weight over a long period. Participants in the study will be randomly assigned to receive either CagriSema or a "dummy medicine" (which looks like the real medicine but has no active ingredients). The study has two parts: the first part lasts for 2 years, and if participants continue into the second part, it will last another year. During the second part, those who received the dummy medicine will start taking CagriSema, while those who took CagriSema may have their dose gradually reduced.

To be eligible for this trial, participants need to be at least 18 years old and have a body mass index (BMI) of 35 or higher, which indicates obesity. However, individuals with certain health conditions, like diabetes, cannot participate. Throughout the study, participants will be closely monitored for any side effects from the medication. It’s important to note that CagriSema is not yet available for doctors to prescribe, so this study is a crucial step in understanding its long-term effects on weight loss.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Male or female.
• • Age above or equal to 18 years at the time of signing informed consent.
• • Body mass index (BMI) greater than or equal to (\>=) 35.0 kilograms per meter square (kg/m\^2).
• Exclusion criteria:
• • Glycated haemoglobin (HbA1c) \>= 6.5 percent (48 millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening.
• • History of type 1 or type 2 diabetes.